51 results about "Interstitial fibrosis" patented technology

The invention discloses a cordycepin extract and notoginseng extract and application in prevention and cure pulmonary fibrosis medicine preparation, which is characterized by the following: extracting and condensing from China clothing hairs pore zymocyte powder with water and alcohol; getting cordycepin extract; setting Cordyceps sinensis adenosine, cordycepic acid, and Cordyceps sinensis polysaccharide more than raw bacteria powder about 3-8 double; extracting cordycepin extract from cordycepin crude drug with alcohol; separating large aperture absorption resin; purifying; getting the cordycepin extract; setting the content of cordycepin saponin more than raw cordycepin crude drug for 7-10 double; allocating the cordycepin and cordycepin saponin with mass percent at 90-10% and 10-90%; preparing medicinal compound. This invention possesses very big utility value in clinic.

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens.

The present invention is directed to a method of treating a subject for a pulmonary disease by administering a therapeutically effective amount of a compound of the formula:

wherein R₁, R₂ or R₃ are each independently a C₁ to C₆ alkyl, a halogen, a sulfate, or a phosphate. The pulmonary disease in the subject can be hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome, atrial septal defects, and pulmonary diseases associated with other conditions. If this same compound is modified so that R₁, R₂ or R₃ each independently is a C₁ to C₆ alkyl and the compound is not a carbonic acid inhibitor, it can be administered to a subject to block hypoxic pulmonary vasoconstriction and/or prevent high altitude pulmonary edema. Additional aspects of the present invention include an inhalable composition comprising the compound of the above formula without modification and an inhalable carrier, as well as the above modified compound.

The invention belongs to the technical field of a biological preparation, and discloses a novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome and a preparation method. The novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome has main component of cup-shaped membrane-shaped vesicles which are prepared through combination of intracellular multivesicular bodies with cell membranes, are secreted outside cells and are about 100nm in size. The preparation method of the novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome comprises an ultracentrifugation method, a chemical reagent precipitation method, an ultrafiltration and centrifugation method and a magnetic bead immunization method. When the MSC cell exosome is extracted and used for treatment of an animal model suffering from diabetic nephropathy, the inventor finds that MSC-Ex has the treatment effects of restraining YAP activity, allevaiting renal interstitial fibrosis and delaying diabetic nephropathy.

The invention provides application of a nuclear receptor ROR alpha in the preparation of anti-heart failure drugs. The nuclear receptor ROR alpha is a nuclear receptor ROR alpha 1 subtype; the gene sequence of the nuclear receptor ROR alpha 1 is as shown in SEQ ID NO. 1; and the amino acid sequence of the nuclear receptor ROR alpha 1 is as shown in SEQ ID NO. 2. Experiments find that the expression of the nuclear receptor ROR alpha provided by the invention in hypertrophic and failing myocardial tissues is down-regulated, and the loss of ROR alpha can aggravate cardiac hypertrophy and cardiacfailure. The overexpression of myocardial-specific ROR alpha can alleviate TAC-induced myocardial interstitial fibrosis and improve the cardiac hypertrophy and cardiac failure. The nuclear receptor ROR alpha has an effect against cardiac hypertrophy and cardiac failure.

The invention discloses the application of CTRP3 to preparation of drugs for preventing and treating cardiac hypertrophy. A pathologic hypertrophy model of cells is established in the invention, and the pathologic hypertrophy model proves that administration of CTRP3 can lower the expression of cardiac hypertrophy marker molecules and reduce the average surface area of cardiac muscle cells. An in-vivo animal model is also established in the invention, and the in-vivo animal model proves that after administration of CTRP3, the heart-to-body ratio and the lung-to-body ratio of a mouse significantly decrease, the left ventricular systolic function of the heart of the mouse is significantly improved; interventricular septal thickness in a systolic period and left ventricular posterior wall thickness in a diastolic period are significantly reduced; the cross-sectional areas of myocardial cells significantly decrease; the myocardial cells are arranged more closely and regularly; the degreesof myocardial tissue interstitial fibrosis and pericapillary fibrosis are greatly lowered; and thus, it is indicated that CTRP3 has significant prevention effect on pathological cardiac hypertrophy, delays the occurrence of heart failures, and has good clinical application prospects.

The invention provides application of oridonin in preparation of cardiac remodeling resistant medicines as well as a cardiac remodeling resistant medicine taking oridonin as a unique active ingredient or a main active ingredient. The invention provides novel medicinal use of the oridonin for preparing the cardiac remodeling resistant medicine. The oridonin can achieve the effects of alleviating cardiac remodeling, inhibiting or delaying cardiomyocyte hypertrophy and cardiac interstitial fibrosis caused by a pressure load, protecting the heart and preventing deterioration of the cardiac function. The oridonin has the advantages of obvious cardiac remodeling resistant effect, low cardiotoxicity and the like.

The invention relates to applications of Kindlin-2 protein as a target point in preparing medicines for treating nephritis. The research result shows that after the Kindlin-2 gene is specifically knocked out, the content of urine protein of mice is obviously increased, while the content of plasma protein is obviously reduced, meanwhile, the structure of glomeruli of the kidney is severely damaged, and the obvious glomerular sclerosis and interstitial fibrosis exist. The experimental result of the research shows that Kindlin-2 protein can be taken as a novel target point for preparing the medicines for treating nephritis.

The invention relates to an application of tetrahydroberberrubine in preparation of a heart protection medicine. Pharmacological experiments of tetrahydroberberrubine show that tetrahydroberberrubine can significantly improve cardiac dysfunction induced by pressure load, and has an obvious heart protection effect; and meanwhile, myocardial cell hypertrophy and interstitial fibrosis can be remarkably inhibited, the heart remodeling process is prevented, and the heart is prevented from entering the heart failure stage. In addition, the tetrahydroberberrubine compound is high in bioavailability, low in toxicity, stable and easy to produce, transport, store and take, and is a heart protection medicine with a wide application prospect.

The invention discloses biomagnetic traditional Chinese medicine for treating a lung disease and a preparation method of the biomagnetic traditional Chinese medicine. The preparation method of the biomagnetic traditional Chinese medicine comprises the following steps: step A, selecting and washing traditional Chinese medicine raw materials of radix panacis quinquefolii, bulbus fritillariae ussuriensis, fructus trichosanthis, semen armeniacae amarae, radix astragali seu hedysari, bulbus lilii, radix ophiopogonis, radix rehmanniae preparata and liquorice root, and mixing the traditional Chinesemedicine raw materials, thus forming a traditional Chinese medicine mixture; step B, soaking the traditional Chinese medicine mixture for 0.5 to 2 hours, decocting for 10 to 20 minutes, and separatingmedicine residue and first liquid medicine; step C, adding water in the medicine residue, decocting for 15 to 25 minutes, and separating the medicine residue and second liquid medicine. The biomagnetic traditional Chinese medicine for treating the lung disease, disclosed by the invention, has a very obvious therapeutic effect; the biomagnetic traditional Chinese medicine has the effects of rapidly penetrating through a focus and removing diffusive pulmonary parenchyma and pulmonary alveolitis; a biomagnetic medicine filed (H) has the effects of penetrating, softening and activating the focuson interstitial fibrosis, and pathogenic cells and virus activating factors are cleared while benign cells are recovered.

The invention provides a composition for improving kidney dysfunction and belongs to the technical field of ginseng deep-processing. The composition comprises, by weight, 2-6 parts of ginsenoside Rg2,1-5 parts of ginsenoside Rg5 and 1-3 parts of ginsenoside Rk1. The composition participates in slowing down the progress of chronic kidney interstitial fibrosis by inhibiting HK-2 phenotypic differentiation so as to improve chronic kidney dysfunction. It is verified that the composition can remarkably improve kidney functions of patients at 2-3 stages of chronic kidney dysfunction CKD.

The invention provides cordyceps cicadae composite medicine for treating diabetic nephropathy and a preparation method thereof and belongs to the field of traditional Chinese medicine. The cordyceps cicadae composite medicine for treating diabetic nephropathy is prepared from the following raw materials in parts by weight: 18 to 22 parts of cordyceps cicadae, 14 to 16 parts of radix rehmanniae, 14to 16 parts of common yam rhizome, 8 to 12 parts of fructus lycii, 8 to 12 parts of fructus corni, 8 to 12 parts of achyranthes root, 14 to 16 parts of fried radix astragali seu hedysari, 8 to 12 parts of radix salvia miltiorrhizae, 8 to 12 parts of poria with hostwood and 5 to 7 parts of chamomile flower. The composite medicine has scientific and rigovous compatibility and complete assistant andguide and has the effects of tonifying qi and yin, promoting blood circulation to remove blood stasis, nourishing liver and kidney and can achieve an effect of treating both symptoms and root causeson the diabetic nephropathy. Research data show that aqueous extract of the cordyceps cicadae composite medicine can effectively inhibit aldose reductase and reduce expression of TGF-beta1 protein, alpha-SMA protein and FN protein of renal tubular epithelial cells; thus, damage to the glomerulus cells is reduced, glomerular sclerosis is relieved, tubular interstitial fibrosis is inhibited, pathological change of the kidney is lightened, illness state development can be inhibited and converted, and a better treating and protecting effect on the diabetic nephropathy is achieved.

The invention relates to the technical field of biological medicines, in particular to application of lactucopicrin in preparation of a medicine for preventing and treating heart failure and pathological cardiac remodeling. The medicine takes the lactucopicrin as an active ingredient, which can be mixed with pharmaceutically acceptable, inert and non-toxic excipients or carrier auxiliary materials to prepare the clinical medicine convenient for oral administration or intravenous application. Specifically, the invention relates to application of the lactucopicrin in preparation of a medicine for resisting heart failure, application of the lactucopicrin in preparation of a medicine for resisting cardiac insufficiency, application of the lactucopicrin in preparation of a medicine for resisting pathological cardiac remodeling, an effect of the lactucopicrin in preparation of a medicine for resisting cardiomyocyte hypertrophy, application of the lactucopicrin in preparation of a medicine for resisting myocardial interstitial fibrosis and application of the lactucopicrin in preparation of a medicine for resisting myocardial cell death.

The invention discloses application of radix plumbaginis zeylanicae to the preparation of a drug for treating a pulmonary fibrosis disease. The invention also discloses the drug for treating the pulmonary fibrosis disease. The drug is prepared from the radix plumbaginis zeylanicae and a pharmaceutically acceptable carrier. Discovered for the first time by the inventor of the application, the radixplumbaginis zeylanicae can be used for obviously inhibiting the proliferation of a fibroblast of pulmonary tissue, and can be used for effectively treating the interstitial fibrosis of the pulmonarytissue. The drug provided by the invention is low in cost, has no toxic and side effects, has an obvious curative effect on the pulmonary fibrosis disease, and is short in treatment period and beneficial to popularization.